Below you will find a regularly updated list of potential funding opportunities for those looking to undertake COVID-19 research.

Funding opportunities and guidance are evolving as the COVID-19 pandemic continues. If you can offer funding for research during the pandemic, or are aware of other organisations offering research funding that are not featured below, please get in touch and let us know.

COVID-19 Funding Dashboards

The following organisations are maintaining lists of funding opportunities for COVID-19 research:

  • GloPID-R Resources
    List of downloadable learning resources, funding opportunities, webinars and publications, all of which have been developed by GloPID-R members
  • Frontiers Cornonavirus Funding Monitor
    A curated list of open funding calls and other support for researchers, non-profit organizations and commercial organizations, specifically for COVID-19 and coronavirus-related research. Updated daily.
  • UKCDR - Funding Calls Dashboard
    The UK Collaborative on Development Research has developed a dashboard for the latest COVID-19 R&D funding opportunities. These range from major initiatives to small research grants, workshop and travel grants, prizes and awards, and individual fellowships and studentships. The dashboard collates funding opportunities for international development research based in the UK, but calls look to support international projects and work in LMICs.
  • RECOVR Funding Opportunities
    This page lists COVID-19-related funding opportunities, including both IPA-eligible and non-IPA-eligible opportunities

 

Specific COVID-19 Funding Sources

Organisation

Areas of Interest 

Further Information

CEPI: Complementary clinical trials: Expanding access to COVID-19 vaccines and rapid response to clinical development gaps

 

 

This is a new funding opportunity of up to US $140 million, contingent upon availability of funds, for clinical trials with the aim to rapidly expand access to and confidence in COVID-19 vaccines by

i) generating clinical evidence in special / sub-populations / age groups or

ii) addressing clinical development gaps. Clinical trials which expand access and capacity in low- and middle-income countries (LMICs) are particularly encouraged.

The Call for Proposals asks for an Expression of Interest (EOI) with a brief description of the current status of the project and a high-level Clinical Development Plan supporting initial emergency use approval / (conditional) licensure or similar. An outline of the proposed clinical trial and targeted label claims (supported by a study protocol synopsis), as well as regulatory and operational considerations for conduct of the clinical trial will be required. For clinical development gaps related to COVID-19 vaccines, please also see the report of the WHO consultation held 15 January 2021.

Applicants should state in what positive ways the proposal can contribute to CEPI’s mission of increasing access to affordable vaccines to low- and middle-income countries, and if there is any willingness to support the provision of vaccine doses, as appropriate, via the COVAX facility.

This Call is open for EOIs from January 28 2021 to May 28 2021. EOIs will be reviewed on a rolling basis. 

Details and How To Apply: Further information on the scope of funding, eligibility and application review criteria and application instructions are available in our Call Text (English, FrenchSpanishChinese, Japanese).

Download our application form to submit an Express of Interest. CEPI reviews and evaluates proposals on their merits in the context of stated eligibility criteria, CEPI’s overall project portfolio and the equitable access benefits of the proposal. Regardless of eligibility at any stage of a funding Call, CEPI, in its sole discretion, reserves the right to consider and to decline any proposal.

Technical and administrative questions about this Call should be directed to cfp@cepi.net

WHO: Establishment of a COVID-19 mRNA vaccine technology transfer hub to scale up global manufacturing

Expression of interest. 

WHO and its partners are seeking to expand the capacity of low- and middle-income countries (LMICs) to produce COVID-19 vaccines and scale up manufacturing to increase global access to these critical tools to bring the pandemic under control.

WHO will facilitate the establishment of one (or more, as appropriate) technology transfer hub(s) that will  use a hub and spoke model (REF) to transfer a comprehensive technology package and provide appropriate training to interested manufacturers in LMICs. This initiative will initially prioritize the mRNA-vaccine technology but could expand to other technologies in the future.

It is anticipated that WHO will work with funders and donors to mobilize financial support to establish the hubs and, as they are being established, to support the transfer of technology to selected manufacturers in LMICs, taking into consideration the need to establish permanent vaccine production capacity in regions where this is currently mostly absent. This broader objective will ensure that all WHO regions will be able to produce vaccines as essential preparedness measures against future infectious threats.

To support this activity, we are seeking expressions of interest from:

  1. Small/middle-sized (public or private) manufacturers of medical products (drugs, vaccines or drug substances) preferably, but not exclusively, in LMICs, which could host a COVID-19 mRNA hub and:
    • Assemble the technology up to good manufacturing practices-grade pilot lots for clinical trials;
    • Transfer the appropriate know-how and technology to existing or new manufacturers in LMICs to enable them to develop and produce COVID-19 mRNA vaccines;
  2. Owners (public or private) of technology and/or intellectual property rights. These may be academic institutions, pharmaceutical companies, non-governmental organizations or any other entity willing to contribute these to a technology transfer hub, under the auspices of WHO, to enable production of mRNA-based COVID-19 vaccines in LMICs.

For this initial expression of interest, entities willing to be considered as a technology transfer hub (as briefly described above under 1) or able to provide the necessary know-how, process training, and intellectual property rights (as briefly described above under 2), are invited to provide a brief summary of their capacity, and their interest in participating in the establishment of a COVID-19 vaccine technology transfer hub to:

Martin Friede (friedem@who.int) and Raj Long (rlong@who.int)

A call for interest from manufacturers in LMICs interested in receiving the technology developed by the technology transfer hub(s) will be issued by WHO in the coming weeks. Preference will be given to manufacturers of drugs, vaccines or active pharmaceutical substances based in LMICs and capable of producing medical products on a large scale under Good Manufacturing Practices. 

More information is available on the WHO website.


UKRI:
 Emergency route for time-critical COVID-19 research

Apply for funding to support short term time-sensitive collection of data or samples or rapid turn-around research or analysis to either:

  • inform urgent policy or national decision making
  • secure data for future research use.
 

To apply you must be able to meet strict criteria, including, but not limited to:

  • demonstrating the time-critical nature of the research or data/sample collection
  • demonstrating a clear and rapid route to impact through existing partnerships
  • showing how a normal grant timeframe is unsuitable
  • justifying why you did not apply through any of the previously available UKRI COVID-19 funding schemes
  • having a clear plan to take this research forward including, if necessary, using normal grant routes.

Before applying, you should check the details of projects that are already funded to avoid duplicating existing work. You can also check our current priority areas to see what we think is important.

 

 

The maximum funding that may be sought is £80,000 (80% full economic cost) and includes any facilities costs.

The usual duration will be 3 months, with a maximum of up to 6 months when necessary.

Applicants must be based at research organisations eligible for UKRI funding. Business-led proposals are not eligible for this funding.

Send your expression of interest as an email attachment to CV19researchinnovation@ukri.org.

National Science Foundation

The NSF is considering proposals for cooperative projects involving U.S. and foreign organizations.

  • To conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19.

  • To inform and educate about the science of virus transmission and prevention.

  • To encourage the development of processes and actions to address this global challenge.

Requests for the Rapid Response Research (RAPID) funding mechanism may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to: rapid-covid19@nsf.gov


Biomedical Advanced Research and Development Authority

BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement.

  • Diagnostic assays for human pan-coronaviruses

  • Point-of-Care diagnostic assays for SARS-CoV-2 virus

  • Diagnostic assay to detect COVID-19 disease

  • Nonclinical model

  • Vaccines for novel coronavirus

  • Therapeutics for novel coronavirus

  • Ventilators

  • Immunomodulators or therapeutics targeting lung repair

  • Pre-exposure and post-exposure prophylaxis for novel coronavirus exposure

  • Respiratory protective devices

  • Advanced Manufacturing Technologies

'If you are interested in partnering on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners! Submit a brief description and supporting materials through our CoronaWatch Portal.'